Endocrine Abstracts

Introduction: Chronic Kidney disease is one of the leading causes of morbidity and mortality worldwide especially among people with diabetes. Finerenone is non-steroidal emerging mineralocorticoid receptor Finerenone has proved to reduce albuminuria and delay the progression of CKD and reduce the cardiovascular risk in non-diabetic population. It is not known whether finerenone has the same effect in non-diabetic CKD. I used finerenone in a case of microalbuminuria in a female diagnosed with congenital lipodystrophy (images available) with normal HbA1c and preserved e GFR. Congenital Lipodystrophy is a group of genetic disorders characterized by severe insulin resistance and loss of adipose tissue with subsequent fat accumulation in the heart, kidneys, liver and ovaries. 22-year-old female presented with acromegalic facies lean body habitus and severe acanthosis nigricans. Her labs showed significantly elevated triglyceride more than 1000 mg/dl HbA1c 5.7%, Albumin-creatinine ratio was 50 mg/g, e-GFR was 120 ml/min, replacement of metreleptin isn’t available in my country so I had to delay the progression of her albuminuria. She was given Finerenone 20 mg based on her serum potassium once daily for 3 months. After 3 months her albuminuria declined to 23 mg/g.